


## 5L(0 plat 500 105 Rec d PCT/PTO 21 APR 1997



#4

PATENT/Docket No.: 4798.P CP

CERTIFICATE OF MAILING (37 CFR 1.8) Date of Deposit with U.S. Postal Service:
I hereby certify that this paper is being deposited with the United States Postal Service as first class mail under 37 CFR 1.8 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington D.C. 20231.
Julie Lyons, Legal Technician Name of Person Mailing Paper Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit

:

Examiner

.

Applicant(s)

K.R. Romines, et al.

Serial No.

08/809,224

Filed

4 May 1995

For

Compounds Useful to Treat Retroviral Infections

Commissioner of Patents and Trademarks Washington, DC 20231

## INFORMATION DISCLOSURE STATEMENT TRANSMITTAL UNDER 37 CFR 1.97 AND 1.98

Sir:

Information Disclosed. The information disclosed consists of the following:

- [] Form PL-1449. Provided herewith are copies of patent(s) and/or publication(s) as listed in the attached form PL-1449.
  - [] At least to the extent required under §1.98(a)(3), a concise explanation of the relevance of references listed in form PL-1449 is:
    - [] contained in the above-captioned specification as filed;
    - [] provided in a communication enclosed with this paper; and/or
    - [] provided in the International Search Report enclosed with this paper.
- [X] Disclosure from Predecessor Application. Provided herewith is a copy (or the copy is already present in the present file wrapper in accordance with §1.62) of one or more forms PL-1449 and/or search/examination reports of record in this or a predecessor application, U.S. Serial No. 08/349,361 filed 2 December 1994, and U.S. Serial No. 08/238,817, filed 6 May 1994, the benefit of which is claimed under 35 USC 120. Copies of references are present in the prosecution history of the referenced application and are not supplied herewith pursuant to §1.98(d).

PATENT/Docket No.: 4798.P CP Serial No.: PCT/US95/05219

Page No. 2

**Basis for Consideration.** This information disclosure statement is entitled to consideration by the Office under:

[X] §1.97(b), as being filed within three months of the filing date of the above-captioned application and/or the date of entry of the National Stage, if later, and/or before the mailing date of the first Office action on the merits. Applicant(s) is are unaware that any office action has issued in this case. However, in the event a first office action has issued, prior to the mailing of this document, then authorization is given to charge the late fee to the deposit account identified below.

[] §1.97(c), as being filed after the period specified in §1.97(b), but before the mailing date of a final action under §1.113 and/or the notice of allowance under §1.311.

Authorization is hereby provided to charge Deposit Account No. 21-0718 the fee set forth in §1.17(p), \$220.00, or such greater or lesser amount as the Commissioner may from time to time prescribe by rule. Triplicate copies of this paper are provided to facilitate the charge to the Deposit Account.

**Disclaimer.** In accordance with §1.97(g) and (h), the filing of this information disclosure statement is not to be construed as an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56, and is not to be construed as a representation that a search has been made.

Respectfully submitted,

Date: 15 April 1997

Martha A. Gammill, Attorney
Registration No. 31 820

Registration No. 31,820 Telephone: (616) 833-7829

Mlg. Address: Intellectual Property Legal Services, Pharmacia & Upjohn Company, Kalamazoo, MI 49001

## Attachment(s):

[] PL-1449 with copies of reference(s)

[X] PL-1449 from predecessor application (no references)

[] Communication providing concise explanation of relevance

[X] International Search Report